Jonathan M. Rothberg

Jonathan Marc Rothberg (born April 28, 1963) is an American scientist and entrepreneur. He is best known for his contributions to next-generation DNA sequencing. He works and resides in Guilford, Connecticut.

Early life

Rothberg was born in New Haven, Connecticut to Lillian Rothberg and Henry Rothberg, a chemical engineer. Prior to Rothberg's birth, his parents founded Laticrete International, Inc. a family-owned manufacturer of products for the installation of tile and stone. As a child Jonathan went on sales calls with his father. Rothberg's family laid the foundation for his scientific career.

Education and scientific career

Rothberg earned a BS in chemical engineering with an option in biomedical engineering from Carnegie Mellon University in 1985. He then went on to earn an MS, MPhil, and PhD in biology from Yale University.

Rothberg himself holds more than 100 patents.

Business career

CuraGen

While a graduate student at Yale, he founded CuraGen, one of the first genomics companies in 1991. CuraGen went public in 1999. By the next year it had a market cap of $5 billion, bigger than that of American Airlines. Rothberg resigned as chief executive of CuraGen in 2005.

454 Life Sciences

In 2000, 454 Life Sciences was founded as a subsidiary of CuraGen; Rothberg was the CEO of CuraGen at the time. The idea for 454 Life Sciences came when Noah, his second child, was born in 1999, and had to be sent to the neonatal intensive care unit because of breathing troubles. Noah turned out to be fine, but Rothberg was frustrated that doctors did not have a rapid test to ensure his son did not have an inherited disease. Rothberg brought to market a machine for massively parallel DNA sequencing. 454 Life Sciences and the Baylor College of Medicine Genome Center were the first to complete and make public the sequence of an individual human genome (James D. WatsonProject Jim: Watson’s Personal Genome Goes Public
at Bio-IT World.com). Published in ''Nature'' magazine, that genome was made publicly on GenBank and browsable via the efforts of Lincoln Stein's group contributing to personal genomics.James Watson's Personal Genome Sequence
Rothberg lost control of 454 Life Sciences by 2007. The company was acquired by Roche Diagnostics in 2007 for $140 million then closed down by Roche in 2013 after other approaches to sequencing rendered the underlying technology noncompetitive.

In 2004, Rothberg founded RainDance Technologies, which used droplet-based microfluidics. RainDance was acquired in 2017 by Bio-Rad Laboratories, Inc.

Ion Torrent

Rothberg founded Ion Torrent in 2007, which developed ion semiconductor sequencing, a technology utilized by their Personal Genome Machine (PGM) DNA sequencer.Ion Torrent Official Webpage.
He founded the company with an undisclosed amount of his own money and later took in $23 million in venture capital. After experiences at CuraGen and 454 Life Sciences, he made sure to retain supervoting share majority so he could not be forced out. At the time, the PGM device was the smallest and cheapest DNA decoder to hit the market. It was able to read 10 million base pairs of DNA in two hours, and sold for $50,000. In 2010, Ion Torrent was acquired for $375 million in cash and stock upfront, plus as much as $350 million later if sales were to reach certain levels.

4Catalyzer

Rothberg established a startup accelerator called 4Catalyzer in Guilford, CT, in the early 2010s. 4Catalyzer companies are positioned at the intersection of Healthcare and Technology, each tackling a different challenge with the common goal of democratizing medicine and maximizing societal impact. The companies focus on using inflection points in medicine, such as deep learning, next-generation sequencing, and the silicon supply chain, to address global healthcare challenges. 4Catalyzer companies include Butterfly Network, Quantum-Si, Hyperfine, Tesseract Health, Liminal Sciences, Detect, AI Therapeutics, and Protein Evolution, Inc.

Butterfly Network

In 2011, Rothberg founded Butterfly Network after seeing a talk by MIT physicist Max Tegmark, who was becoming fascinated by artificial intelligence. Rothberg brought in one of Tegmark's smartest students, Nevada Sanchez, a co-founder of the company who was named among Forbes 30 Under 30 in 2015. Butterfly Network sells a hand-held ultrasound imaging device that connects to an iPhone, called the iQ. The core technology is a silicon chip, contrasting with other ultrasound devices that use piezoelectric crystals. The use of silicon makes the device far cheaper to manufacture. The iQ received 13 different device clearances from the Food and Drug Administration. The iQ sells for just over $2,000, and is now commercially available. In September, 2018, Butterfly Network raised $250 million from investors Fidelity, the Gates Foundation, and Fosun Pharma at an estimated $1.25 billion valuation. In February 2021 Butterfly Network was publicly listed on the NYSE under the ticker $BFLY.

Quantum-Si

Rothberg founded Quantum-Si in 2013 with the mission of transforming single molecule analysis and democratizing its use by providing researchers and clinicians access to the proteome, the set of proteins expressed within a cell. In 2021 Quantum-Si went public on the NASDAQ under the ticker $QSI.

In February 2022, Rothberg became interim CEO of Quantum-Si.

Hyperfine

In 2014, Rothberg founded Hyperfine to develop the world's first portable MRI scanner that can be transported easily between patients and costs a fraction of traditional MRI. Hyperfine received FDA clearance in 2021 to add deep-learning algorithms to boost the quality of images. The Hyperfine Swoop is commercially available and saving lives on multiple continents around the world, including limited resource settings in Africa and Asia where access to MRI was never before possible. Hyperfine went public in December 2021 and is listed on the NASDAQ under the ticker, $HYPR.

Detect

Dr. Rothberg launched Detect in partnership with consumer electronics veteran and now Detect CEO Hugo Barra at the outset of the Covid-19 pandemic with the goal of bringing rapid, affordable lab-quality pathogen testing into the home.

Detect’s first product is the FDA-authorized Detect Covid-19 Test, the most affordable molecular (i.e. PCR-quality) rapid test in the U.S., which they brought to market in a record-setting 18 months from company founding. The customer reception and press coverage of the product has been overwhelmingly positive.

As the emphasis on Covid-19 subsides, Detect is focused on building a robust roadmap of the lowest cost, highest quality at-home diagnostics products in their industry, and a full stack of services that enables them to sell 'total solutions' into the healthcare payer landscape.

Detect is building a future where people test themselves for infections, chronic disease and wellness in the comfort and privacy of their home. Their initial focus is on common infectious disease management, specifically Covid+Flu, Strep Throat, and STIs—which are collectively responsible for an economic burden north of $50B annually in the U.S. alone—and over the next few years they will expand into the even-larger multi hundred billion dollar chronic disease management market. Their long-term northstar is a universal personal diagnostic device that will be a cornerstone of a societal-level shift to individual health empowerment and preventative care.

Tesseract Health

Tesseract was founded in 2018 to build technology at the nexus of radiology and laboratory medicine on the diagnostic tree. The company
aims to support the screening, diagnosis, and monitoring of disease, both affordably and non-invasively using the power of data in the human eye.

Liminal Sciences

Dr. Rothberg founded Liminal in 2018 with the goal of building a wearable brain monitor for acute and chronic conditions including stroke, traumatic brain injury, hydrocephalus, and epilepsy. Inspired by both the utility and the limitations of EEG (electroencephalogram), Liminal has invented AEG, a new modality that combines blood flow measurement with the existing technology that monitors the electrical activity of the brain. Liminal enables critical “brain vital signs” to make brain monitoring as ubiquitous as heart monitoring.

Protein Evolution, Inc.

PEI leverages artificial intelligence to build profitable products in the bioeconomy: the first of which is an infinite recycling solution for plastic waste.

Personal life

Rothberg and his wife Bonnie, a physician who also holds a Ph.D. in epidemiology from Yale, have five children, whom Rothberg often refers to in his speeches. In 2002, the couple started the nonprofit Rothberg Institute for Childhood Diseases which works on treatments for tuberous sclerosis, a rare disease that affects one of their children. The institute ran a distributed computing project called Community TSC until April 2009. The TSC project was based on technology known as the Drug Design and Optimization Lab (D2OL), which the institute sponsored through 2009, to use volunteers' personal computers to model interactions of drug candidates with their target molecules.

Rothberg sponsors the Rothberg Catalyzer Prize at four universities: Carnegie Mellon University, Yale University, Brown University, and University of Pennsylvania.

Rothberg had his own version of Stonehenge, which he calls the Circle of Life, built near his home in Guilford, CT, using 700 tons of granite imported from Norway. Interested in wine-making, he acquired Chamard Vineyards in nearby Clinton, CT. Rothberg owns a yacht called ''Gene Machine,'' which is equipped with a lab on board, and its support vessel, ''Gene Chaser''.

Recognition

Rothberg was awarded the National Medal of Technology and Innovation by President Barack Obama in 2016 for his “pioneering inventions and commercialization of next-generation DNA sequencing technologies, making access to genomic information easier, faster and more cost-effective for researchers around the world".

Rothberg received the Connecticut Medal of Technology in 2010. In 2012, Rothberg was awarded the Wilbur Cross Medal as a distinguished alumni from Yale University. Rothberg made Fortune Magazine's 2001 list of the 40 richest Americans under 40. Rothberg was elected a member of the National Academy of Engineering in 2004 for the application of engineering principles to the mining of genomic information for the discovery and development of new drugs.

References

External links

*

4Catalyzer

Butterfly Network

Quantum-Si

Hyperfine

Tesseract Health

Liminal Sciences

Detect

AI Therapeutics

Protein Evolution, Inc.

{{DEFAULTSORT:Rothberg, Jonathan M.
1963 births
Living people
21st-century American biologists
Members of the United States National Academy of Engineering
Carnegie Mellon University College of Engineering alumni
Carnegie Mellon University trustees
Yale University alumni